Treatment with the combination of the CD47-targeting antibody magrolimab and azacitidine induced high response rates, particularly in patients with myelodysplastic syndromes. David A. Sallman, MD, discusses findings from an ongoing phase Ib trial.
Recent Articles
Is It Too Soon to Celebrate the Cancer Death Rate Decline?
Earlier this year, the American Cancer Society reported the biggest one-year decline in cancer mortality ever recorded from 2016 to 2017. While fewer deaths...
Trump Administration Fetal Tissue Restrictions Disrupt Research
A recent decision by the Trump administration to limit funding for research using fetal tissue is changing scientists’ research paths and disrupting research into...
Current Issue
January 2020 Annual Meeting Edition
This issue features highlights from the 2019 ASH Annual Meeting, reflections on physician wellness, and more.
